Wahl, R.L.; Frey, E.C.; Jacene, H.A.; Kahl, B.S.; Piantadosi, S.; Bianco, J.A.; Hammes, R.J.; Jung, M.; Kasecamp, W.; He, B.;
et al. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers 2021, 13, 2828.
https://doi.org/10.3390/cancers13112828
AMA Style
Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B,
et al. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers. 2021; 13(11):2828.
https://doi.org/10.3390/cancers13112828
Chicago/Turabian Style
Wahl, Richard L., Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco, Richard J. Hammes, Miah Jung, Wayne Kasecamp, Bin He,
and et al. 2021. "Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels" Cancers 13, no. 11: 2828.
https://doi.org/10.3390/cancers13112828
APA Style
Wahl, R. L., Frey, E. C., Jacene, H. A., Kahl, B. S., Piantadosi, S., Bianco, J. A., Hammes, R. J., Jung, M., Kasecamp, W., He, B., Sgouros, G., Flinn, I. W., & Swinnen, L. J.
(2021). Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers, 13(11), 2828.
https://doi.org/10.3390/cancers13112828